What Luminex does

Luminex Corporation, founded in 1995 and headquartered in Austin, Texas, develops and commercializes bead-based multiplex testing technologies under the xMAP platform. The company's core technology uses proprietary MagPlex magnetic microspheres with internal dye classification to simultaneously measure up to 500 analytes (proteins and nucleic acids) from a single sample. Its product portfolio spans four instrument tiers — xMAP INTELLIFLEX, FLEXMAP 3D, LUMINEX 200, and MAGPIX — addressing high-throughput, mid-throughput, and compact benchtop use cases. The instruments are supported by a consumables ecosystem that includes MagPlex, MagPlex-Avidin, MagPlex-TAG, MagPlex Monitoring, MicroPlex, and SeroMAP microspheres, an antibody coupling kit, magnetic separators, and xPONENT instrument-control and data-analysis software.

Luminex operates a razor-and-blade revenue model: instrument sales (hardware) drive the installed base, while recurring sales of proprietary microsphere reagents generate ongoing consumables revenue. A material portion of assay content is developed by third parties — Bio-Rad, Thermo Fisher (Invitrogen), MilliporeSigma, R&D Systems, Active Motif, and Prime Diagnostics — and distributed through the xMAP Kit Finder, creating a platform ecosystem that extends the company's commercial reach without proportional internal assay-development cost. Customers are distributed across five segments: clinical diagnostics (transplant monitoring, autoimmune, infectious disease, oncology, allergy), biopharma and drug development, academic research, public health, and applied technologies (food safety, microbiome). The company maintains a global footprint across North America (USA), Europe (UK, Switzerland), and Asia Pacific (Japan, China).

Since 2021, Luminex has operated as a wholly-owned subsidiary of DiaSorin, the Italian diagnostics group, and is positioned as DiaSorin's Luminex Licensed Technology Group. Distribution, sales, and corporate functions are delivered through DiaSorin infrastructure. Reported ownership of the xMAP trademark, MagPlex microspheres, and xPONENT software, together with the multi-decade installed base, is the foundation of a defensible niche in the global multiplex assay market, which is estimated at $1.82 billion in 2025 and projected to reach $3.89 billion by 2033 at a 10% CAGR, with Luminex holding approximately 38% of the North America segment.

Name

Luminex

Legal name

Luminex Corporation

Website

https://luminexcorp.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Luminex, a DiaSorin subsidiary, develops bead-based xMAP multiplexing instruments and proprietary MagPlex microsphere reagents for clinical diagnostics, biopharma, academic, public health, and applied testing laboratories globally.

Ownership category

akta.pro rank

Product category

Multiplex Assay Instruments and Reagents

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

Keywords

• Multiplex immunoassays
• Bead-based multiplexing
• Clinical diagnostics instruments
• Protein biomarker analysis
• Molecular diagnostics reagents

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Instrument Sales: Sale of xMAP multiplexing instruments including xMAP INTELLIFLEX, FLEXMAP 3D, LUMINEX 200, and MAGPIX systems.
2. Microsphere Reagents: Recurring sales of proprietary MagPlex, MicroPlex, and SeroMAP microspheres for use on xMAP instruments.
3. Coupling Accessories and Kits: Sales of antibody coupling kits, magnetic separators, and specialty microsphere products.
4. Software Licensing: Licensing of xPONENT software for instrument control and data acquisition.
5. Partner Kit Finder Ecosystem: Third-party kit manufacturers (Bio-Rad, Invitrogen, MilliporeSigma, R&D Systems) develop and sell xMAP-compatible assays, creating a platform ecosystem revenue model.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Luminex develops, manufactures, and markets biological testing technologies based on its proprietary xMAP bead-based multiplexing platform, sold to clinical diagnostics laboratories, life science researchers, pharmaceutical and biotechnology companies, and public-health organizations. Its commercial offerings comprise flow-cytometry-based multiplex instruments, MagPlex/MicroPlex/SeroMAP magnetic and carboxylated microsphere reagents, antibody coupling kits and magnetic separators, the xPONENT software for data acquisition and analysis, and the xMAP Cookbook and Kit Finder tool ecosystem supporting partner-developed assays.

Product overview

Luminex, a subsidiary of Diasorin, offers the xMAP Technology platform — the world's most widely used multiplexing technology for both protein and nucleic acid-based assays. The portfolio comprises four instrument tiers (xMAP INTELLIFLEX, FLEXMAP 3D, LUMINEX 200, and MAGPIX) serving varying throughput needs, supported by a comprehensive microsphere family (MagPlex, MagPlex-Avidin, MagPlex-TAG, MagPlex Monitoring, MicroPlex, SeroMAP) and accessory products (xMAP Antibody Coupling Kit, Magnetic Separators). The xPONENT Software provides instrument control and data acquisition, while the xMAP Kit Finder and xMAP Cookbook serve as resource tools — the former enabling discovery of partner-developed commercial kits (Active Motif, Bio-Rad, Invitrogen, MilliporeSigma, R&D Systems, Prime Diagnostics) and the latter providing assay development protocols. The platform enables simultaneous measurement of up to 500 analytes from a single sample, with applications spanning clinical diagnostics (transplant, autoimmune, infectious diseases, oncology, allergy), applied technologies (microbiome, food/feed testing), biopharma (drug discovery, vaccine development), public health, and academic research.

Differentiator

Problem solved

Functional benefit

Brands

• xMAP: The world's most used multiplexing technology platform enabling protein and nucleic acid-based multiplex assays
• xMAP INTELLIFLEX
• FLEXMAP 3D
• MAGPIX
• MagPlex Microspheres

Products and services

• xMAP INTELLIFLEX System Dual-laser flow cytometry-based multiplex reader for running xMAP bead-based assays, supporting simultaneous quantification of up to 500 analytes per well for clinical diagnostics and life science research laboratories.
• FLEXMAP 3D System High-throughput multiplex flow cytometry-based instrument for running xMAP bead-based assays, supporting up to 500 analytes per well in research and clinical laboratory workflows.
• LUMINEX 200 System Flow cytometry-based multiplex instrument for running xMAP bead assays across clinical diagnostics, drug discovery, and research laboratories.
• MAGPIX System Compact imaging-based magnetic bead reader that uses MagPlex microspheres for xMAP multiplex assays targeted at lower-throughput clinical and research labs.
• MagPlex Microsphere Family Superparamagnetic microsphere reagents, including MagPlex-TAG, MagPlex-Avidin, and MagPlex Monitoring variants, used as the consumable bead substrate for xMAP-based multiplex assays.
• MicroPlex Microspheres Carboxylated polystyrene (non-magnetic) microspheres sized for non-magnetic xMAP workflows and custom multiplex assay development.
• SeroMAP Microspheres Serology-grade microspheres optimized for serum- and plasma-based multiplex assays, including infectious disease and autoantibody panels.
• xMAP Antibody Coupling Kit Two-step amine coupling kit for covalently attaching proteins (antibodies or antigens) to xMAP microspheres for custom multiplex assay development.
• Magnetic Separators Magnetic accessory used to wash and separate MagPlex microspheres during multiplex assay workflows, including handheld and plate-format separators.
• xPONENT Software Proprietary data acquisition, instrument control, and analysis software used with xMAP flow-cytometry-based multiplex instruments, including in clinical 21 CFR Part 11 environments.
• xMAP Kit Finder Searchable tool maintained by Luminex that indexes partner-developed assay kits validated for the xMAP platform, helping customers find compatible kits across applications.
• xMAP Cookbook Reference resource of recipes, methods, and protocols for designing and running xMAP Technology-based assays, provided as a technical tool to aid laboratory users.

Quantifiable outcome

• Global Luminex Multiplex Assays Market valued at USD 1.82 billion in 2025, projected to USD 3.89 billion by 2033 at 10% CAGR

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• SMi SystemscoreStrategic or Co-development Partner · 2 June 2026SMi Systems announced a non-exclusive evaluation collaboration with Luminex Corporation to assess feasibility of using Luminex beads with SMi's single-molecule imaging platform. The partnership targets the $1.8 billion global multiplex assay market, with initial focus on research activities to validate whether SMi's 1.6-nanometer resolution imaging can complement Luminex's xMAP technology. If successful, integration could enable earlier disease detection in oncology, immunology, and vaccine development.
• SMi SystemscoreTechnology or Integration · 2 June 2026Non-exclusive evaluation collaboration to compare analytical sensitivity of SMi's single-molecule imaging platform against Luminex's existing xMAP readers under defined test conditions. Initial phase focuses on research activities to validate technology complementarity.
• Bio-Rad LaboratoriescoreChannel Partner/ Reseller/ DistributorBio-Rad is a certified xMAP partner offering ProcartaPlex protein assays and QuantiGene Plex gene expression assays through the xMAP Kit Finder ecosystem.
• Thermo Fisher Scientific (Applied Biosystems/ Invitrogen)coreChannel Partner/ Reseller/ DistributorThermo Fisher Scientific offers Invitrogen ProcartaPlex protein assays and Invitrogen QuantiGene Plex gene expression assays through the xMAP partner network.
• MilliporeSigmacoreChannel Partner/ Reseller/ DistributorMilliporeSigma provides xMAP-compatible assay products through the xMAP Kit Finder partner ecosystem.
• R&D SystemscoreChannel Partner/ Reseller/ DistributorR&D Systems offers multiplex assay kits compatible with xMAP technology through the partner program.
• Active MotifminorChannel Partner/ Reseller/ DistributorActive Motif develops and distributes xMAP-compatible kits for research applications.
• Prime DiagnosticsminorChannel Partner/ Reseller/ DistributorPrime Diagnostics provides xMAP-compatible assay kits through the partner network.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Meso Scale Diagnostics (MSD): MSD's electrochemiluminescence U-PLEX and V-PLEX platforms provide bead-based multiplex immunoassays in the same high-sensitivity protein-biomarker workflows served by xMAP INTELLIFLEX and FLEXMAP 3D, competing head-to-head in pharma/biopharma biomarker validation.
• Cytek Biosciences: Cytek's Aurora and Northern Lights spectral flow cytometers are increasingly used as the flow-cytometry read platform underneath bead-based multiplexed assays, positioning Cytek as a direct hardware competitor to the FLEXMAP 3D and INTELLIFLEX readers.
• Bio-Rad Laboratories: Bio-Rad sells the Bio-Plex system, the most direct bead-based multiplex competitor to Luminex xMAP, using similar flow-cytometry detection and offering ProcartaPlex kits through the very same xMAP partner ecosystem, which makes it simultaneously a partner and a direct rival.

Broad incumbents

• Sartorius: Sartorius's lab bioprocessing and cellular analysis instrumentation (including acquired BIA Separations and assets from Pall) compete for the same cell-based and potency-assay budget that Luminex's MAGPIX and INTELLIFLEX platforms serve in cell-therapy and biopharma workflows.
• Thermo Fisher Scientific: Thermo Fisher distributes Invitrogen ProcartaPlex multiplex kits on the xMAP partner network (same as Luminex), but its broader portfolio of Qubit, KingFisher, Attune NxT flow cytometers, and Orbitrap mass spectrometers increasingly overlaps with Luminex's research and clinical diagnostics customers.
• MilliporeSigma (Merck KGaA Life Science): MilliporeSigma supplies MILLIPLEX multiplex kits run on Luminex xMAP instruments today (partner channel) while also offering its own broader portfolio of bead-based and cell-based assay reagents that compete for the same research budget.
• Revvity (formerly PerkinElmer Life Sciences): Revvity offers multiplex immunoassay reagents and a broad diagnostics/life-sciences instrument portfolio that overlaps with Luminex in clinical and research biomarker testing and in cellular analysis workflows.
• Abbott (Diagnostics): Abbott's Alinity and ARCHITECT immunoassay systems compete with Luminex for clinical diagnostics market share in infectious disease, autoimmune, and transplant monitoring, offering fully automated random-access workflows versus Luminex's lower-throughput multiplex workstations.

Emerging players

• Quanterix: Quanterix's Simoa single-molecule array technology offers ultra-high sensitivity protein detection at lower plex than xMAP, and is positioning itself as a complementary or replacement technology for neurology, oncology, and infectious-disease biomarker work currently served by Luminex.
• Olink: Olink's proximity extension assay (PEA) technology (Target 96/48 and Explore platforms) is an emerging single-protein-at-a-time multiplex alternative that goes head-to-head with Luminex in plasma proteomics, biomarker discovery, and pharma biomarker validation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/luminex
• Facebookfacebook.com/LuminexCorp
• LinkedInlinkedin.com/company/luminex-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luminex